Anika Therapeutics has launched Orthovisc mini, a smaller dosage indication of Orthovisc for treatment of osteoarthritis of the knee in the EU.
Subscribe to our email newsletter
The company is also initiating a post-approval clinical study of Orthovisc mini to gain additional clinical experience with regional opinion leaders who specialize in the treatment of osteoarthritis in small joints.
Charles Sherwood, Anika’s president and CEO, said: “We will utilize our existing European Orthovisc distribution network for this new product, and anticipate filling initial orders before the end of the first quarter of 2008.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.